Sagimet Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sagimet Biosciences Inc. (SGMT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-45.57-27.88-30.50-24.44-11.37
Stock Based Compensation5.294.991.881.900.78
Change in Working Capital-1.05-0.984.21-0.060.08
Change in Accounts Payable-0.910.122.920.56-0.36
Change in Other Working Capital0.150.141.300.130.44
Other Operating Activities0.150.140.130.130.12
Net Cash from Operating Activities-42.44-23.77-24.49-21.71-10.42
Investing Activities
Purchases of Investments-108.09-19.62-32.010.000.00
Sales/Maturities of Investments46.4032.209.440.000.00
Net Cash from Investing Activities-61.6812.58-32.010.000.02
Financing Activities
Common Stock Issued105.7589.680.010.190.00
Other Financing Activities-1.05-3.52-0.09-1.250.00
Net Cash from Financing Activities104.8286.17-0.079.7468.89
Summary
Net Change in Cash0.7074.98-56.57-11.9758.49
Cash at Beginning of Period75.140.1656.7368.700.00
Cash at End of Period75.8475.140.1656.730.00
Free Cash Flow-42.44-23.77-24.49-21.710.00